Earnings Flash (RKDA) ARCADIA BIOSCIENCES Reports Q1 Revenue $1.26M, Vs. Street Est of $1.19M
04:32 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (RKDA) ARCADIA BIOSCIENCES Reports Q1 Revenue $1.26M, vs. Street Est of $1.19M
Press Release: Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights -- Revenues increase sequentially and year-over-year -- -- Loss from continuing operations is at low
Express News | Arcadia Biosciences Q1 Net Income USD -2.423 Million
Express News | Arcadia Biosciences Q1 EPS USD -1.78
Arcadia Biosciences (RKDA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference Call
Arcadia Biosciences, Inc. (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first
SNDL, Arcadia Biosciences Among Consumer Staples Movers
Arcadia Cold Sets Its Sights on Chicago
Company finalizing plans for multi-facility footprint in the Chicagoland market for their next two cold storage facilities. ATLANTA, April 17, 2024 /PRNewswire/ -- Arcadia Cold, a leading cold stor
Express News | Arcadia Biosciences Inc: Raises $50M to Accelerate Product Innovation and Fuel Continued Growth
Buy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product Launches
HC Wainwright & Co. Reiterates Buy on Arcadia Biosciences, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Arcadia Biosciences (NASDAQ:RKDA) with a Buy and maintains $10 price target.
Arcadia Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 392.61% HC Wainwright & Co. → $10 Reiterates Buy → Buy 08/28/2023 392.61% HC Wainwright & Co. $
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript
Buy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic Shifts
Arcadia Biosciences Full Year 2023 Earnings: Misses Expectations
Q4 2023 Arcadia Biosciences Inc Earnings Call
Earnings Call Summary | Arcadia Biosciences(RKDA.US) Q4 2023 Earnings Conference
The following is a summary of the Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript:Financial Performance:Arcadia reported Q4 revenues of $1.2 million, up 57% compared to Q4 2022, driv
Recap: Arcadia Biosciences Q4 Earnings
Arcadia Biosciences (NASDAQ:RKDA) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsArcadia Biosciences beat es
Arcadia Biosciences GAAP EPS of -$2.10 Beats by $0.48, Revenue of $1.17M Misses by $0.58M
Press Release: Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights -- Second continuous year of gross profit growth -- -- Total SG&A expenses declined t
No Data